All In Biotech

Drug Trial Radar · NCT07270835

Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma

The Study of Zanubrutinib Combined With Rituximab in the Treatment of Secondary Hemophagocytic Lymphohistiocytosis in B-cell Lymphoma

Last checked: Nov 20, 2026Latest source record: Dec 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Nov 1, 2025

Primary completion

Apr 2027

Study completion Aug 2027

Sponsor

Lead sponsor
The First Affiliated Hospital of Soochow UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 14 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

For patients who met the inclusion criteria, treatment regimens were administered: Rituximab 375 mg/m², intravenously, once weekly for 4 weeks. Zanubrutinib 160 mg, orally, twice daily for 4 weeks. Combined drugs: prednisone 100 mg/m²/d, orally, d1-5; Ruxolitinib 15mg bid orally; With/without emapalumab as appropriate.

Conditions

  • Hemophagocytic Lymphohistiocytosis
  • B Cell Lymphoma

Interventions

  • RituximabDrug

    375 mg/m², intravenously, once weekly for 4 weeks

  • ZanubrutinibDrug

    160 mg, orally, twice daily for 4 weeks as for rutuximab.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. response rate of HLH after 4 weeks of treatmentTime frame: after 4 weeks
  2. OS at week 8Time frame: after 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.